Rock Springs Capital CORT Position
Active3-Fund ConvergenceRock Springs Capital initiated a new position in Corcept Therapeutics Inc. (CORT) in Q4 2025, holding $1.7M worth of shares across 50,250 shares.
CORT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Relacorilant 150 mg once daily (QD) in 137 days (Aug 31, 2026), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 16.5% of float with 7.1 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
About Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Full company profile →Short Interest
16.5%
7.1 days to cover
Frequently Asked Questions
Does Rock Springs Capital own CORT?
Yes. As of Q4 2025, Rock Springs Capital holds 50,250 shares of Corcept Therapeutics Inc. (CORT) valued at $1.7M. This data comes from their SEC 13F filing.
How many hedge funds own CORT?
3 specialist biotech hedge funds currently hold CORT, including Driehaus Capital, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy CORT?
Rock Springs Capital's position in CORT was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's CORT position increasing or decreasing?
Rock Springs Capital initiated a new position in CORT in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CORTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →